Hinge Health Q3 2026 earnings
Record Q3 revenue and free cash flow with raised full-year guidance and margin expansion.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $235.0M | +52% | +10.5% | Ex. 99.1, Financial Highlights |
| EPS (GAAP) | $0.66 | +N/A | +0.14 | Ex. 99.1, Financial Highlights |
| EPS (adjusted) | $0.71 | +121% | +0.12 | Ex. 99.1, Financial Highlights |
| Net income | $57.4M | +N/A | +13.7M | Ex. 99.1, Financial Highlights |
| Adj. EBITDA | $77.2M | +154% | +15.7M | Ex. 99.1, Financial Highlights |
| Adj. EBITDA margin | 33% | +13 pp | +4 pp | Ex. 99.1, Financial Highlights |
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin 87% (prior 82%, change +5 pp)
- Operating expenses $154.0M (+16.6% YoY)
- One-offs in the quarter Acquisition-related expenses: $80k; Acquisition-related expenses: $2.6M (Non-GAAP)
- Effective tax rate N/A
- Non-GAAP bridge Adds back stock-based compensation, employer payroll tax, amortization, and acquisition-related expenses.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Free cash flow | $112.7M | $99.6M | $81.3M | +13.1M QoQ, +38.4% YoY |
| LTM billings | $960.3M | $861.8M | $624.2M | +98.5M QoQ, +54% YoY |
| Number of clients | 3,270 | 2,929 | 2,560 | +341 QoQ, +28% YoY |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Q4 2026 Revenue | $249M-$251M | $223M-$225M | +26M-$28M |
| Q4 2026 Non-GAAP Operating Margin | 33% (midpoint) | 28% (midpoint) | +5 pp |
| FY 2026 Revenue | $879M-$881M | $856M-$860M | +23M-$25M |
| FY 2026 Non-GAAP Operating Margin | 30% (midpoint) | 28% (midpoint) | +2 pp |
What drove it
- Revenue story Revenue increased 52% YoY to $235.0M, driven by continued high member conversion and a record sales season.
- EPS story Non-GAAP EPS increased 121% YoY to $0.71, driven by revenue growth and margin expansion.
- One-off check Acquisition-related expenses of $80k (GAAP) and $2.6M (Non-GAAP) for Cylinder Health.
The good
- Revenue grew 52% YoY to $235.0M
- Free cash flow increased to $112.7M
- Non-GAAP operating margin expanded to 33%
The bad
- none
The ugly
- none
Open questions
- Details on the integration and synergies of the Cylinder Health acquisition
- Specifics on the launch timeline for the integrated Gastrointestinal Care Program
Full release
Hinge Health (HNGE) earnings release, November 2, 2026
Hinge Health reports record third quarter 2026 financial results
• Revenue increased 52% year-over-year to $235 million
• Free cash flow of $113 million, representing a 48% free cash flow margin
• 2026 revenue guidance midpoint raised to $880 million, reflecting 50% year-over-year growth
• 2026 non-GAAP operating margin midpoint raised to 30%, reflecting ~1,000 bps improvement year-over-year
San Francisco, California – November 2, 2026 – Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the third quarter ended September 30, 2026 and provided a business update.
“Our strong performance continues to reflect our ability to deliver exceptional clinical outcomes, a better healthcare experience and lower client costs at scale," said Daniel Perez, Co-Founder and CEO, Hinge Health. "This focus on the triple aim, via a technology platform that scales and automates care delivery, is also resulting in a record sales season. Our client base is up almost 30% YoY for our MSK Care Program, roughly 40% for our GI Care Program since our acquisition announcement of Cylinder Health in August, and has nearly doubled for our Migraine Care Program since last quarter."
Third Quarter Financial Highlights:
• Revenue increased 52% year-over-year to $235.0 million compared to revenue of $154.2 million in Q3 2025.
• GAAP gross margin was 87% compared to 82% in Q3 2025.
Non-GAAP gross margin was 88% compared to 83% in Q3 2025.
• GAAP income from operations increased to $50.3 million compared to GAAP loss from operations of $6.1 million in Q3 2025.
Non-GAAP income from operations increased 154% to $77.2 million compared to $30.4 million in Q3 2025.
• GAAP operating margin was 21% compared to (4)% in Q3 2025.
Non-GAAP operating margin was 33% compared to 20% in Q3 2025.
• GAAP diluted net income per share was $0.66 compared to a GAAP diluted net loss per share of $0.
02 in Q3
2025.
Non-GAAP diluted net income per share was
$0.71 compared to $0.32 in Q3 2025.
• Net cash provided by operating activities increased to $114.6 million compared to $82.4 million in Q3 2025.
Free cash flow increased to $112.7 million compared to $81.3 million in Q3 2025.
• Cash, cash equivalents, marketable securities and restricted cash were $358.5 million as of September 30, 2026.
Company Highlights and Key Metrics:
• LTM calculated billings increased 54% year-over-year to $960.3 million as of September 30, 2026, compared to $624.2 million as of September 30, 2025.
• Number of clients increased 28% year-over-year to 3,270 clients as of September 30, 2026, compared to 2,560 clients as of September 30, 2025.
Leadership Update
We also announced that Jim Pursley will step down as President, effective January 1, 2027, and will join our Board of Directors, effective January 4, 2027. Following this transition, Aaryn Pure will lead the commercial organization as Chief Commercial Officer.¹
“We wouldn't be the company we are today if not for Jim,” said Daniel Perez, Co-Founder and CEO, Hinge Health. “He's been instrumental in our scaling to over 3,200 clients. I'm grateful for all he's done and that he'll continue contributing to our success as a board member and advisor.”
Financial Outlook:
We are providing the following guidance for our fourth quarter 2026 and full year 2026:
• Q4 2026:
We expect revenue to be between $249 million and $251 million, reflecting year-over-year growth of 46% at the midpoint. We expect non-GAAP income from operations to be between $81 million and $83 million, reflecting year-over-year growth of 71% and non-GAAP operating margin of 33% at the midpoint, a ~470 bps increase over Q4 2025.
• Full Year 2026:
We are raising our revenue guidance to be between $879 million and $881 million, reflecting year-over-year growth of 50% at the midpoint. We are raising our non-GAAP income from operations guidance to be between $266 million and $268 million, reflecting year-over-year growth of 123% and non-GAAP operating margin of 30% at the midpoint, a ~1,000 bps increase over 2025.
Statement Regarding Use of Non-GAAP Financial Measures
This press release uses non-GAAP financial measures, which are not calculated in accordance with generally accepted accounting principles of the United States (GAAP). For more information about these non-GAAP financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP, please see the “Non-GAAP Financial Measures” section below.
Moreover, we have not reconciled our non-GAAP income from operations and non-GAAP operating margin guidance to GAAP income from operations and GAAP operating margin because we do not and are not able to provide guidance for GAAP income from operations due to the uncertainty and potential variability of stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets and adjustments, such as acquisition-related expense, which are reconciling items between non-GAAP and GAAP income from operations and operating margin. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measures. However, such items could have a significant impact on our future GAAP income from operations.
Hinge Health Earnings Webcast
We will host a conference call and webcast for investors on November 2, 2026 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss our financial results, business highlights and financial outlook. The live webcast of the conference call can be accessed by registering online at ir.hingehealth.com/events-presentations. Following completion of the event, a webcast replay will also be available at ir.hingehealth.com for 12 months.
About Hinge Health... (truncated)ealth care. Leveraging an AI-powered care model, connected hardware and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that improves member outcomes and experiences while reducing costs for clients. The company is headquartered in San Francisco, California.
Available Information
Our investors and others should note that we announce material information to the public about our company, products and services, and other matters related to our company through a variety of means, including filings with the U.S. Securities and Exchange Commission (“SEC”), the investor relations page on our website (ir.hingehealth.com), press releases, public conference calls, and webcasts in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our obligations under Regulation FD.²
Financial statements
Income Statement
Three Months Ended September 30, — (in thousands, except per share data)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| Revenue | 234,970 | 154,211 | 630,094 | 417,134 |
| Cost of revenue | 30,640 | 28,012 | 87,582 | 92,939 |
| Gross profit | 204,330 | 126,199 | 542,512 | 324,195 |
| Operating expenses: | ||||
| Research and development | 37,473 | 31,921 | 101,868 | 335,382 |
| Sales and marketing | 85,241 | 63,520 | 235,451 | 257,464 |
| General and administrative | 31,291 | 36,851 | 82,359 | 304,976 |
| Total operating expenses | 154,005 | 132,292 | 419,678 | 897,822 |
| Income (loss) from operations | 50,325 | -6,093 | 122,834 | -573,627 |
| Other income: | ||||
| Other income, net | 3,392 | 4,455 | 11,255 | 14,147 |
| Net income (loss) before income taxes | 53,717 | -1,638 | 134,089 | -559,480 |
| (Benefit from) provision for income taxes | -3,681 | 206 | -2,128 | 876 |
| Net income (loss) | 57,398 | -1,844 | 136,217 | -560,356 |
| Adjustment to reflect deemed contribution from Series D and Series E redeemable convertible preferred stock extinguishment | 104,174 | |||
| Income allocated to participating securities | -2,051 | |||
| Net income (loss) attributable to common stockholders, basic | 57,398 | -1,844 | 134,166 | -456,182 |
| Net income (loss) attributable to common stockholders, diluted | 57,398 | -1,844 | 134,307 | -456,182 |
| Net income (loss) attributable to common stockholders per share: | ||||
| Basic | 0.71 | -0.02 | 1.69 | -9.88 |
| Diluted | 0.66 | -0.02 | 1.58 | -9.88 |
| Weighted average shares used in computing net income (loss) per share attributable to common stockholders: | ||||
| Basic | 80,868 | 78,858 | 79,493 | 46,173 |
| Diluted | 86,526 | 78,858 | 85,073 | 46,173 |
Income Statement
Three Months Ended September 30, — Reconciliation of GAAP to Non-GAAP Financial Measures:
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| GAAP gross profit | 204,330 | 126,199 | 542,512 | 324,195 |
| GAAP gross margin | 87 | 82 | 86 | 78 |
| Non-GAAP adjustments: | ||||
| Stock-based compensation expense (1) | 959 | 1,401 | 2,924 | 17,842 |
| Employer payroll tax expense related to stock-based compensation | 134 | 40 | 284 | 933 |
| Amortization of intangible assets | 649 | 224 | 1,098 | 630 |
| Acquisition-related expenses | 80 | 80 | ||
| Non-GAAP gross profit | 206,152 | 127,864 | 546,898 | 343,600 |
| Non-GAAP gross margin | 88 | 83 | 87 | 82 |
Income Statement
Three Months Ended September 30, — Reconciliation of GAAP to Non-GAAP Financial Measures:
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| GAAP income (loss) from operations | 50,325 | -6,093 | 122,834 | -573,627 |
| GAAP operating margin | 21 | -4 | 19 | -138 |
| Non-GAAP adjustments: | ||||
| Stock-based compensation expense (1) | 19,540 | 34,847 | 50,324 | 625,837 |
| Employer payroll tax expense related to stock-based compensation | 3,516 | 228 | 6,316 | 14,455 |
| Amortization of intangible assets | 1,211 | 224 | 1,660 | 630 |
| Acquisition-related expenses | 2,617 | 1,171 | 3,751 | 4,139 |
| Non-GAAP income from operations | 77,209 | 30,377 | 184,885 | 71,434 |
| Non-GAAP operating margin | 33 | 20 | 29 | 17 |
Income Statement
Three Months Ended September 30, — Stock-based compensation expense:
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| Cost of revenue | 959 | 1,401 | 2,924 | 17,842 |
| Research and development | 7,551 | 8,259 | 18,102 | 257,068 |
| Sales and marketing | 6,050 | 5,960 | 16,019 | 101,010 |
| General and administrative | 4,980 | 19,227 | 13,279 | 249,917 |
| Total stock-based compensation expense | 19,540 | 34,847 | 50,324 | 625,837 |
Balance Sheet
September 30, 2026 — (in thousands, except par value data)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | 211,553 | 207,995 |
| Short-term marketable securities | 83,102 | 155,867 |
| Accounts receivable, net of allowance for credit losses of $7,647 and $6,092 as of September 30, 2026 and December 31, 2025, respectively | 148,532 | 66,061 |
| Deferred commissions | 46,599 | 31,344 |
| Inventory | 19,186 | 15,636 |
| Prepaid expenses and other current assets | 58,891 | 57,001 |
| Total current assets | 567,863 | 533,904 |
| Long-term marketable securities | 59,542 | 113,172 |
| Goodwill | 113,030 | 64,096 |
| Intangible assets, net | 68,328 | 2,512 |
| Property, equipment and software, net | 13,989 | 10,490 |
| Operating lease right-of-use assets | 33,317 | 6,861 |
| Other assets | 18,012 | 13,726 |
| Total assets | 874,081 | 744,761 |
| Current liabilities: | ||
| Accounts payable and accrued liabilities | 80,816 | 57,331 |
| Operating lease liabilities | 4,721 | 4,223 |
| Deferred revenue | 459,174 | 300,855 |
| Total current liabilities | 544,711 | 362,409 |
Cash Flow
Three Months Ended September 30, — (in thousands)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| Operating activities: | ||||
| Net income (loss) | 57,398 | -1,844 | 136,217 | -560,356 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||||
| Depreciation and amortization | 2,221 | 1,264 | 4,455 | 3,910 |
| Stock-based compensation | 19,540 | 34,847 | 50,324 | 625,837 |
| Amortization of deferred commissions | 21,716 | 12,566 | 57,006 | 32,436 |
| Accretion of discounts and amortization of premiums on marketable securities, net | 551 | 50 | 1,255 | 376 |
| Non-cash operating lease expense | 1,152 | 861 | 2,986 | 2,549 |
| Provision for credit losses | 914 | 560 | 2,527 | 3,340 |
| Deferred taxes | -3,313 | 50 | -3,300 | 146 |
| Other | 4 | -2 | 2 | |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | -18,418 | 11,974 | -79,402 | -47,610 |
| Deferred commissions | -25,167 | -10,670 | -74,246 | -38,320 |
| Inventory | -2,119 | 175 | -3,251 | -2,939 |
| Prepaid expenses and other current assets | 9,405 | -1,393 | -1,915 | -8,002 |
| Other assets | 492 | -7,664 | 165 | -8,149 |
| Accounts payable and accrued liabilities | 9,998 | 17,993 | 12,590 | 24,990 |
| Operating lease liabilities | -898 | -932 | -3,052 | -2,724 |
| Deferred revenue | 41,130 | 24,557 | 156,741 | 82,062 |
| Net cash provided by operating activities | 114,602 | 82,398 | 259,098 | 107,548 |
| Investing activities: | ||||
| Purchase of property and equipment | -376 | -52 | -582 | -300 |
| Capitalized internal use software | -1,568 | -1,065 | -4,746 | -3,401 |
| Purchases of marketable securities | -142,898 | -89,877 | -318,180 | |
| Maturities of marketable securities | 44,157 | 85,258 | 214,117 | 249,814 |
| Acquisition of a business, net of cash acquired | -97,353 | -97,353 | -4,000 | |
| Cash paid for an asset acquisition | -9,036 | -9,036 | ||
| Net cash provided by (used in) investing activities | -64,176 | -58,757 | 12,523 | -76,067 |
| Financing activities: | ||||
| Proceeds from exercise of common stock options | 202 | 531 | 882 | 787 |
| Issuance of common stock in connection with the employee stock purchase plan | 7,276 | |||
| Proceeds from issuance of common stock in initial public offering, net of issuance costs | 255,675 | |||
| Repurchase and retirement of common stock | -25,893 | -157,384 | ||
| Tax withholdings on settlement of restricted stock units and performance-based restricted stock units | -96,565 | -116,356 | -272,258 | |
| Payment on Repurchase Agreement with Coatue | -50,000 | |||
| Proceeds from repayment of non-recourse loans to employees | 4,934 | |||
| Payments for deferred offering costs | -10,061 | |||
| Net cash provided by (used in) financing activities | -122,256 | 531 | -265,582 | -70,923 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -71,830 | 24,172 | 6,039 | -39,442 |
| Cash, cash equivalents, and restricted cash, beginning of period | 287,665 | 238,972 | 209,796 | 302,586 |
| Cash, cash equivalents, and restricted cash, end of period | 215,835 | 263,144 | 215,835 | 263,144 |
| Reconciliation of cash, cash equivalents, and restricted cash to the unaudited condensed consolidated balance sheets: | ||||
| Cash and cash equivalents | 211,553 | 261,342 | 211,553 | 261,342 |
| Restricted cash | 4,282 | 1,802 | 4,282 | 1,802 |
| Total cash, cash equivalents, and restricted cash | 215,835 | 263,144 | 215,835 | 263,144 |
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” or “will,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding the integration, timing and anticipated benefits and synergies associated with the acquisition of Cylinder Health, statements regarding our expectations regarding our financial position and operating performance, including our outlook and guidance for the fourth quarter of 2026 and guidance for full year 2026 and our assumptions underlying such guidance; our planned leadership transitions; our ability to drive future growth and execute on our goals and strategies; and our expectations regarding our product innovation, including with respect to our Migraine Care Program and the anticipated launch of our integrated Gastrointestinal Care Program in 2027. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including those more fully described in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 3, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, when filed with the SEC. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.³